Table 1.
Patient’s characteristics, therapies and clinical outcome
| Age (years) | N | % |
|---|---|---|
| 40–49 | 8 | 23 |
| 50–59 | 11 | 32 |
| 60–69 | 11 | 31 |
| > 70 | 5 | 14 |
| Chemotherapy | ||
| Yes | 8 | 23 |
| No | 27 | 77 |
| Hormone therapy | ||
| Start before RT | 12 | 34 |
| Start after RT | 22 | 63 |
| No | 1 | 3 |
| Tumor size (cm) | ||
| < 1 | 12 | 34 |
| 1–2 | 20 | 57 |
| > 2 | 3 | 9 |
| pTNM | ||
| T1 (a-c) | 30 | 86 |
| T2 | 5 | 14 |
| N0 | 30 | 86 |
| N1 | 5 | 14 |
| M0 | 35 | 100 |
| G1 | 7 | 20 |
| G2 | 26 | 74 |
| G3 | 2 | 6 |
| Hormone receptor status | ||
| Estrogen receptor+ | 35 | 100 |
| Progesteron receptor+ | 35 | 100 |
| Total dose (Gy) | ||
| 40 | 3 | 9 |
| 60 | 27 | 77 |
| 66 | 5 | 14 |
| Total dose of boost (Gy) | ||
| 10 | 25 | 72 |
| 16 | 5 | 14 |
| Clinical outcome | ||
| Disease-free > 3 years |
14 | 40 |
| Disease-free > 5 years |
18 | 52 |
| Endometrial cancer | 1 | 3 |
| Recurrence/metastases | 2 | 6 |